The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental *Schistosoma mansoni* infection in mice

Belén Vicente¹,⁵, Julio López-Abán¹,⁵, Juliane Chaccour², Juan Hernández-Goenaga¹, Patricia Nicolas³, Pedro Fernández-Soto³, Antonio Muro¹ & Carlos Chaccour²,³,⁴

Schistosoma mansoni is less susceptible to the antiparasitic drug ivermectin than other helminths. By inhibiting the P-glycoprotein or cytochrome P450 3A in mice host or parasites in a murine model, we aimed at increasing the sensitivity of *S. mansoni* to the drug and thus preventing infection. We assigned 124 BALB/c mice to no treatment, treatment with ivermectin only or a combination of ivermectin with either cobicistat or elacridar once daily for three days before infecting them with 150 *S. mansoni* cercariae each. The assignment was done by batches without an explicit randomization code. Toxicity was monitored. At eight weeks post-infection, mice were euthanized. We determined number of eggs in intestine and liver, adult worms in portal and mesenteric veins. Disease was assessed by counting granulomas/cm² of liver and studying organ weight indices and total weight. IgG levels in serum were also considered. No difference between groups treated with ivermectin only or in combination with cobicistat or elacridar compared with untreated, infected controls. Most mice treated with ivermectin and elacridar suffered severe neurological toxicity. In conclusion, systemic treatment with ivermectin, even in the presence of pharmacological inhibition of P-glycoprotein or cytochrome P450 3A, did not result in effective prophylaxis for *S. mansoni* infection in an experimental murine model.

Progress in the control or elimination of schistosomiasis must be approached from different angles: accurate, fast and cheap diagnosis; affordable, safe and effective treatment; and well-established prevention and control strategies. WHO has recognized the need to identify new compounds as an alternative to praziquantel, the single therapeutic agent in use today. Although praziquantel remains effective, concerns arise about potential drug resistance stemming from its continuous use in mass drug administration campaigns in endemic areas¹,². Different artemisinin-derived compounds have been developed and tested alone or combined with praziquantel³. Mefloquine has also been used, with good results in experimental models⁴, and edelfosine alone or in combination with praziquantel, with good results in reducing granulomatous inflammation both in vitro and in vivo⁵,⁶.

Ivermectin is a widely used antiparasitic drug⁷. It is the first-line treatment for strongyloidiasis, scabies and onchocerciasis, part of the regimen for lymphatic filariasis (LF) and has demonstrated efficacy against other soil-transmitted helminths⁸. In the mouse model of schistosome infection, adult worm load can be reduced by very high doses of ivermectin⁹, as it appears that *Schistosoma mansoni* is much less susceptible to ivermectin than other helminths⁹. It is unknown whether *S. mansoni* cercariae differ in sensitivity to ivermectin, to date no study has described a prophylactic model.

Decreased susceptibility to ivermectin can be brought about by ATP-binding cassette (ABC) transport proteins and their interaction with cytochrome P450 (CYP) 3A¹¹,¹². We hypothesize that the combination of

---

¹Infectious and Tropical Diseases Group (e-INTRO), IBSAL-CIETUS (Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca), Faculty of Pharmacy, University of Salamanca, Salamanca, Spain. ²Clínica Universidad de Navarra, Pamplona, Spain. ³ISGlobal, Barcelona Institute for Global Health, Hospital Clinic, Universitat de Barcelona, Rosello 132, 5ª 2ª, 08036 Barcelona, Spain. ⁴Ifakara Health Institute, Ifakara 67501, United Republic of Tanzania. ⁵These authors contributed equally: Belén Vicente and Julio López-Abán. ⁶email: carlos.chaccour@isglobal.org
ivermectin and elacridar, a P-glycoprotein inhibitor, or cobicistat, a CYP3A inhibitor, could increase the susceptibility of *S. mansoni* invading schistosomula to ivermectin. The objective of this work was to evaluate the capacity of ivermectin alone and in combination with elacridar or cobicistat to prevent *S. mansoni* infection in an experimental model using BALB/c mice.

**Materials and methods**

**Parasites and animals.** To maintain the *Schistosoma mansoni* (LE strain) cycle, freshwater snails *Biomphalaria glabrata* were used as intermediate hosts, and CD1 mice as definitive hosts. Snails of 4–8 mm in diameter were infected with seven miracidia each. They were kept in 25 °C water for 30 days until the emission of cercariae was induced with light and a temperature of 26 °C for 2 h. Triplicate counts were done to obtain a dose of 150 cercariae in 0.7–1.2 ml of chlorine-free water.

For the infection experiment, 124 SPF BALB/c mice (Charles River, Lyon, France) with a weight of 18.5–21.3 g and an age of seven weeks were used. The animals were kept in a controlled temperature and humidity environment with a 12:12 h light:dark cycle. They were supplied with water and food ad libitum in the facilities of the Animal Experimentation Service of the University of Salamanca according to the current Spanish legislation on animal experimentation (L32/2007, L6/2013 and RD 53/2013) and the transposition of the rules of the European Union (Di 2010/63/CE). All experiments with animals were approved by the Bioethics Committee of the University of Salamanca (Registration number CBE-225). Humane endpoints were applied when an evidence of severe pain, excessive distress, suffering or an impending death was observable in any of the animals, which were then euthanized. All mice were euthanized at the end of the experiment by intraperitoneal injection of sodium pentobarbital in PBS (100 mg/kg). The status of all mice was checked daily using a composite score including vitality, secretions, fur quality, mobility, dyspnea, ascites, neurological signs, and ability to ingest water or food.

All methods were carried out in accordance with relevant guidelines and regulations. All animal handling and methods complied with the ARRIVE guidelines.

**Experimental design.** We used the BALB/c mouse model of infection by *Schistosoma mansoni* established in the IBSAL-CIETUS of the University of Salamanca, Spain. Mice were divided into five experimental groups: untreated uninfected (G1 Untr, n = 9), infected (G2 Inf, n = 45), treated with 1000 μg/kg of ivermectin daily for three days by oral catheter before infection (G3 Iv, n = 30), treated with 1000 μg/kg of ivermectin and 25 mg/kg of cobicistat daily for three days by oral catheter before infection (G4 Iv + Co, n = 30), and treated with 1000 μg/kg of ivermectin and 2.5 mg/kg of elacridar daily for three days by oral catheter before infection (G5 Iv + El, n = 10) (Fig. 1). In G4 and G5, ivermectin was administered 2 h after cobicistat and elacridar.

After each drug administration, the behavior of the animals was observed for potential signs of toxicity (nervous, neuromuscular, digestive). On the third day of treatment and 4 h after administering the ivermectin dose, the animals in group 2, 3, 4 and 5 were infected with 150 cercariae of *S. mansoni* each. The infection was performed after anesthesia with a mixture of ketamine (50 mg/kg), diazepam (5 mg/kg) and atropine (1 mg/kg), in a final volume of 100 μl by intraperitoneal injection in order to immobilize the animals. They were placed supine, a plastic ring was placed on the shaved abdomen, attached with adhesive tape, and the water solution...
EGGs in tissues were (1992 ± 1082 egg per gram of liver and 1493 ± 801 egg per gram of small intestine) with respect to the drug or drug combinations against infection by *S. mansoni*. Mice treated prophylactically with ivermectin showed no significant reduction in the total recovery of adult worms. The animals treated with the combination of ivermectin and cobicistat had a non-significant 8% reduction in worm load compared with the ivermectin group (6–12% reduction) (Fig. 3).

**ELISA for determination of *S. mansoni* soluble somatic antigen (SoSmAWA)-specific IgG.** In order to detect specific antibodies against *S. mansoni* infection, the mouse sera were analyzed by indirect enzyme immunoassay (ELISA), for specific immunoglobulin G (IgG) levels. We used soluble adult somatic antigen from *Schistosoma mansoni* (SoSmAWA) according to Abán et al. (1999)19.

We coated 96-well polystyrene plates (Costar 3369, Corning Inc.) with 2.5 µg of SoSmAWA per well in a final volume of 100 µl of carbonate buffer at pH 9.6 and incubated them for 18 h at 4°C. Plates were washed three times with 200 µl of 1X PBS per well at pH 7.2 and 0.05% Tween (PBS-T) to remove residues of unbound antigen, and blocked with 2% BSA in PBS-T (100 µg per well) at 37°C for 1 h to avoid nonspecific antibody-binding and washed three times. Serum samples from each mouse were incubated for 1 h at 37°C at a 1:100 dilution in PBS-T, and washed as in the previous steps. The secondary mouse ant-IgG antibody (Sigma Aldrich, anti-mouse IgG-peroxidase, A5906) was added at a 1:1000 dilution in PBS-T, incubated for 1 h at 37°C, and washed. The plates were then incubated with o-phenylenediamine dihydrochloride (OPD) as a peroxidase substrate, and H2O2 as an oxidizing agent in citrate buffer at pH 5.0. The reaction was stopped with 50 µl per well of 3 N H2SO4. Absorbance was measured at 492 nm in a spectrophotometer (ThermoScientific Multiskan GO 1510, Finland).

**Statistical analysis.** Data are presented as means and standard errors of the mean. A Bartlett test was carried out to verify the homogeneity of the data distribution of all the variables. A t-unpaired two-tailed ANOVA analysis was done and, if statistically significant, the data was analyzed in a post hoc Fisher’s Least Significant Difference test to determine the existence of significant differences between the study groups. *P*-values below 0.05 were considered significant. A multivariate analysis of main variables was also carried out. For these analyses and work chart, we used Simfit V7.3.0 and Statview V5.0 statistical packages.

**Results**

**Effect of Iv and Iv-Co on the weight of BALB/c mice after infection by *S. mansoni.** Weight loss after the administration of a xenobiotic can be an indicator of toxicity in the protocol used. Healthy animals gained an average of 3.2 ± 0.6 g during the experimental period, whereas infected animals gained 3.6 ± 0.3 g. Animals treated with ivermectin after infection gained 3.5 ± 0.5 g, whereas those treated with ivermectin + cobicistat only gained 2.5 ± 0.5 g. These differences were not statistically significant (Fig. 2).

**Neurotoxicity.** After administering the combination of ivermectin and elacridar to G5 as detailed in "Materials and methods", the animals showed seizures, circular movements, and loss of ambulatory capacity. Six animals in the ivermectin and elacridar group died or were euthanized according to the end-point rules of the protocol. Only four out of ten mice survived the administration of the ivermectin and elacridar drug combination. No deaths or signs of neurotoxicity were seen in the group that was administered ivermectin alone or combined with cobicistat.

The four mice surviving in the elacridar and ivermectin group were infected and necropsy performed at eight weeks post infection. In the necropsy, no differences in worms recovered (8.5 ± 3.5 males, 6.0 ± 3.8 females) and egg in tissues were (1992 ± 1082 egg per gram of liver and 1493 ± 801 egg per gram of small intestine) with respect to other groups were seen, no statistical test was performed given the sample size (n = 4).

**Effect of Iv and Iv-Co on worm recovery.** The parasite load was used to estimate the prophylactic capacity of the drug or drug combinations against infection by *S. mansoni*. Mice treated prophylactically with ivermectin showed no significant reduction in the total recovery of adult worms. The animals treated with the combination of ivermectin and cobicistat had a non-significant 8% reduction in worm load compared with the control group of infected mice. A similar situation occurred in the separate recovery of male and female worms (6–12% reduction) (Fig. 3).

**Effect of Iv and Iv-Co on the number of eggs retained in liver and intestine.** Schistosome eggs in liver and intestine are the most relevant indicator of the severity of the disease. Mice treated with ivermectin or...
the combination of ivermectin and cobicistat did not reveal reductions in the number of eggs per gram of liver or intestine compared with the infected control group (Fig. 4).

Effect of Iv and Iv-Co on S. mansoni granulomas and organ indexes. Granuloma formation is an immune response to the presence of eggs in tissues and it is an indicator of severe disease. There was no reduction in granulomas per liver surface in animals that were administered ivermectin When using the combined ivermectin + cobicistat, the reduction was 3.6% but this was not statistically significant when compared with infected mice (Fig. 5). Hepatic and intestinal indices are indicators of the relative inflammation of each of these organs against the eggs trapped. In schistosome infection, hepato-splenomegaly is described as one of the most prominent signs and is present in severe forms of the disease. Infected mice showed a 350–360% increase in spleen weight (ANOVA $F_{(3,105)}$ 4.439, $p = 0.006$) and a 45–59% increase in liver weight (ANOVA $F_{(3,105)}$ 16.670, $p < 0.001$) compared with the untreated infected mice. The intestinal index increased by 64–72%, which was not statistically significant (Fig. 6).

IgG levels against SoSmAWA in infected animals. Immunoglobulin levels during infection with S. mansoni serve to reveal the status of the infection and the response against the infection of the animals. High levels of specific IgG against the SoSmAWA antigen were observed in all infected groups at eight weeks post-infection. The infected group did not differ significantly from the groups given preventative treatment (Fig. 7).
Multivariate analysis. We included the following variables for the study of principal components (PC): total recovered worms, eggs in tissue, granulomas in the liver, organ indices, weight variation during the experiment and antibody levels at eight weeks post-infection. Between the principal components 1 and 2 (PC1 and PC2), 74% of the information was collected (Fig. 8). We found no differences between the infected groups previously treated with ivermectin (G3 Iv), ivermectin + cobicistat (G4 Iv-Co) or untreated (G2 Inf). Only the untreated and uninfected group (G1 Untreated) differed (Fig. 5). All variables affected both principal component 1 and 2 (Fig. 9).

Regulatory compliance. All methods were carried out in accordance with relevant guidelines and regulations.
Discussion

The discovery of glutamate-mediated signaling in *S. mansoni* raised hopes for new drug targets in this species\(^\text{14}\). Macrocyclic lactones such as ivermectin target the neuronal glutamate-gated chloride channel that is expressed by arthropods, nematodes and trematodes\(^\text{15}\). Schistosomes express these channels, yet the evidence base for the efficacy of ivermectin against *S. mansoni* is inconclusive, which might be explained by a relatively low affinity of the *S. mansoni* glutamate-gated chloride channel for ivermectin\(^\text{16}\). Nevertheless, one study reported a marked reduction in adult worm load after high-dose treatment with ivermectin, which was attributed to the tegumental

---

**Figure 6.** Splenic index (A), hepatic index (B) and intestinal index (C) of mice treated with ivermectin (Iv) and Ivermectin + cobicistat (Iv + Co) and infected with 150 cercariae by *S. mansoni* (Inf) at 8 weeks post-infection. *Statistically significant differences p < 0.05 compared to untreated controls (Untr).*
damage inflicted on the worms. The slight, yet non-significant, reduction in adult worm load observed in our study might indicate a possible dose-dependent effect, as Taman et al. used a 25-fold higher dose of ivermectin. These extremely high doses are contraindicated for systemic human use due to safety concerns. It could be worthwhile exploring a potential alternative approach for targeting the development of schistosome in tissue. We are not aware of data showing differential expression of GluCl channels at different life stages of S. mansoni. L-Glutamate-containing neurons have been reported in cercaria that have not been identified in other life stages. It is, however, unknown if ivermectin treatment affects these life stages differently. Using an inhaled formulation...
against schistosomula stages in the lung might allow for higher concentrations against a developmental stage that is not often targeted17.

In *C. elegans*, the susceptibility to ivermectin can be modulated by targeting ABC transporters or the P-gp18,19. We previously showed in a pharmaco-enhancement model of mosquitoes feeding on treated pigs that the simultaneous inhibition of cytochrome p450 3A and the P-gp enhanced the effect of ivermectin by two mechanisms: by increasing plasma levels in the pig host and by increasing the susceptibility of the mosquito. This combination resulted in prolonged target insecticidal concentrations of the drug able to kill *Anopheles* mosquitoes20.

Given the inconclusive evidence regarding the efficacy of ivermectin treatment in *S. mansoni*-infected mice, we hypothesized that P-gp and CYP3A inhibitors may also alter the susceptibility of *S. mansoni* cercariae to ivermectin in a prophylaxis model.

Despite pharmacological inhibition of CYP and P-gp in our study, ivermectin did not have any significant effect on the numbers of *S. mansoni* eggs or adult worms in the mouse nor on the host immune response as evidenced by a lack of differences in IgG levels or granuloma formation. This finding stands in contrast to Kasiathan et al. who showed a significant effect of P-gp inhibitors in combination with praziquantel on both egg numbers and granuloma size in *S. mansoni*-infected mice, and suggested effects on parasite immunomodulatory factors to the host21. These differences point to different mechanisms involved in the metabolism of praziquantel and ivermectin.

Ivermectin has an excellent safety profile demonstrated over decades in global mass drug administration campaigns. Its safety is partly explained by the activity of P-gp in the capillaries of blood–brain barrier that excludes ivermectin from the mammalian central nervous system. Only a few cases of encephalopathy were described in rare population genotypes (mdr-1 gene) in Loa loa massive drug administration campaigns22.

In our study, the combined use of ivermectin and P-gp inhibitor elacridar led to seizures and disturbances in movement defined as final point criteria in most animals in the treated group. As elacridar disrupts the function of P-gp in the murine blood–brain barrier, elevated ivermectin levels in the brain lead to important neurological toxicity23,24. It serves as a reminder that in states with an impaired blood–brain barrier, as is the case in hyperinflammatory states, ivermectin could cause significant neurological toxicity.

A limitation of this study pertains to our choice of model animal. Although ivermectin does not affect physiological parameters in mice, they are one of the rodent species most susceptible to ivermectin toxicity25. The data on lethal dose included by Merck in the ivermectin label were determined in murine models26. This dose potentially does not represent the true toxicity in larger mammals or humans. The vulnerability of mice to ivermectin toxicity excludes the possibility of using higher doses that might produce more pronounced prophylactic effects against *Schistosoma* infection. Another limitation concerns the standard time span and cercaria dose in which the experiments were conducted to make comparable with other studies. In field conditions people became infected in several times with lower daily doses and measurement time point is difficult to establish. The drug-treated groups were not treated all simultaneously, which might have a small influence on the results.

---

**Figure 9.** Multivariate study of principal components, loads associated with each of the variables used in the study at eight weeks post-infection. Groups: mice treated with ivermectin and infected with 150 cercariae of, *S. mansoni* (Iv); treated with ivermectin + cobicistat (Iv + Co) and infected; infected only with 150 cercariae of (Inf); and an untreated and uninfected control group (Untr). EPG eggs per gram.
Conclusions

Ivermectin did not show prophylactic properties against experimental infection with S. mansoni cercariae. Parasite load, granulomatous lesions, or antibody responses in the ivermectin-treated group were comparable to the untreated control group. Combining ivermectin with cobicistat to prevent infection by S. mansoni did not result in differences in parasite load, granulomatous lesions, or antibody responses compared to the untreated control group. The combination of ivermectin and elacridar led to severe toxicity.

Financial support

This study was supported by the University of Navarra with a generous donation from Jeffery and Heart Deal. CCh and PN received salary support from Unitaid through the BOHEMIA grant to ISGlobal. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. USAID acknowledges support from the Instituto de Salud Carlos III, ISCIII, Spain (http://www.isciii.es) under grants: RICET RD16/0027/0018 and PI19/01727; Ministerio de Ciencia e Innovación (MICINN) Spain RTI2018-099474-B-I00 and European Union co-financing by FEDER (Una manera de hacer Europa, Sistema Nacional de Garantía Juvenil, Cofinanciación por FEDER, and Iniciativa de Empleo Juvenil BDNS: 472002).

Data availability

All study data is contained within this manuscript and the supplementary material.

Received: 6 November 2020; Accepted: 19 January 2021
Published online: 24 February 2021

References

1. Wang, W., Wang, L. & Liang, Y.-S. Susceptibility or resistance of praziquantel in human schistosomiasis: A review. Parasitol. Res. [Internet] 111, 1871–1877. https://doi.org/10.1007/s00438-012-3151-z (2012).
2. Lotto, W. M., El-Hawary, A. S. & Abu El Einin, H. M. Evaluation of a method for induction of praziquantel resistance in Schistosomamansoni. Pharm. Biol. [Internet] 53, 1214–1219. https://doi.org/10.3109/13880209.2014.970289 (2015).
3. Xiao, S. H. Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins. Acta Trop. 96, 153–167 (2005).
4. Keiser, J., et al. Melfloquine—An aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis. [Internet] 3, e350. https://doi.org/10.1371/journal.pntd.0000350 (2009).
5. Yepes, E. et al. In vitro and in vivo ant-schistosomal activity of the alkylphospholipid analog edelfosine. PLoS ONE 9, e109431 (2014).
6. Yepes, E. et al. Inhibition of granulomatous inflammation and prophylactic treatment of schistosomiasis with a combination of edelfosine and praziquantel. PLoS Negl. Trop. Dis. [Internet] 9, e0003893. https://doi.org/10.1371/journal.pntd.0003893 (2015).
7. Oms, S. & Crump, A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. [Internet] 30, 445–455. http://www.sciencedirect.com/science/article/pii/S1471492214001263 (2014).
8. Merck. Stromectol. TGA Australia approved Package insert [Internet]. 2014 [cited 31 Aug 2020]. https://www.ebs.tga.gov.au/ebst/ picmic/picmirepository.nsf/pdf?OpenAgent&Id=CP-2011-P1-02659-38&d=2016071016114622483.
9. Taman, A., El-Beshbibi, S., El-Tantawy, N., El-Hawary, A. & Azab, M. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. J. Coast Life Med. 2, 817–823 (2014).
10. Dufour, V., Beech, R. N., Wever, C., Dent, J. A. & Geary, T. G. Molecular cloning and characterization of novel glutamate-gated chloride channel subunits from Schistosomamansoni. PLoS Pathog. [Internet] 9, e1003586. https://doi.org/10.1371/journal.ppat.1003586 (2013).
11. Seif El-Din, S. H., Abdel-Aal Sabra, A.-N., Hammam, O. A. & El-Lakkany, N. M. Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosomamansoni in mice. Korean J. Parasitol. [Internet] 51, 165–175 (2013).
12. Ziniel, P. D. et al. The Schistosomamansoni cytochrome P450 (CYP305A1) is essential for worm survival and egg development. PLoS Negl. Trop. Dis. [Internet] 9, e0004279. https://doi.org/10.1371/journal.pntd.0004279 (2016).
13. Abin, J. L., et al. A fatty acid binding protein from Fasciola hepatica induced protection in C57/BL mice from challenge infection with Schistosoma bovis. Vet. Parasitol. Netherlands 83, 107–121 (1999).
14. Mendonça-Silva, D. L., Fittipaldi Pessóa, R. & Noël, F. Evidence for the presence of glutamatergic receptors in adult Schistosomamansoni. Biochem. Pharmacol. 64, 1337–1344 (2002).
15. Wolstenholme, A. I on channels and receptor as targets for the control of parasitic nematodes. Int. J. Parasitol. Drugs Drug Resist. 1, 2–13 (2011).
16. Solis-Soto, J. M. & de Jong-Brink, M. Immunocytochemical study on biologically active neurosubstances i daughter sporocysts and cercariae of Trichobilharziacyclocelata and Schistosomamansoni. Parasitology 108, 301–311 (1994).
17. Chacour, C. et al. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Sci. Rep. [Internet] 10, 17073. https://doi.org/10.1038/s41598-020-74084-y (2020).
18. James, C. & Davey, M. Increased expression of ABC transport proteins is associated with ivermectin resistance in the model nematode Caenorhabditis elegans. Int. J. Parasitol. 39, 213–220 (2009).
19. Ardelli, B. & Prichard, R. Inhibition of P-glycoprotein enhances sensitivity of Caenorhabditis elegans to ivermectin. Vet. Parasitol. 191, 264–275 (2013).
20. Chacour, C. et al. Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anoplolepegiae. Sci. Rep. 7, 8535 (2017).
21. Kashihasay, R. S., Sharma, L. K., Cunningham, C., Webb, T. R. & Greenberg, R. M. Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to praziquantel. PLoS Negl. Trop. Dis. [Internet] 8, e3265. https://doi.org/10.1371/journal.pntd.0003265 (2014).
22. Bourguinat, C. et al. Analysis of the mdr-1 gene in patients co-infected with Schistosomamansoni. Pharmacogenet. Genomics [Internet] 2011;11. https://journals.lww.com/pharmacogenetics/Fulltext/2001/11000/Ivermectin_sensitivity_in_collies_is_associated.12.aspx
25. Davis, J. A. et al. Behavioral effects of ivermectin in mice. *Lab. Anim. Sci.* **49**, 288–296 (1999).
26. BV Dohme Merck Sharp & Dohme. FDA-approved package insert [Internet]. 2007 [cited 6 Oct 2020]. https://www.merck.com/product/usa/pi_circulars/s/stromectol/stromectol_pi.pdf.

**Acknowledgements**

We thank Ana Gómez Sánchez and Marta González Leal for their technical help with the *S. mansoni* life cycle, ELISA and animal management.

**Author contributions**

Conceptualization: C.Ch. Data curation: B.V., J.L.A., J.H.G., P.F.S. Formal analysis: B.V., J.L.A., A.M. Funding acquisition: C.Ch. Investigation: B.V., J.L.A., A.M. Methodology: C.Ch., P.N., P.F.S., J.H.G., B.V., J.L.A., A.M. Supervision: A.M. Writing—original draft: J.L.A., B.V., J.Ch., C.Ch. Writing—review and editing: all authors contributed, reviewed and approved the last draft.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to C.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021